Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reena Khanna

Showing results (1-10 of 162) with videos related to

Pageof 17
Sort By:
Gastroenterology|February 2, 2025
The Safety and Efficacy of Guselkumab for the Treatment of Moderate to Severely Active Ulcerative ColitisReena Khanna
Gastroenterology|August 12, 2022
Risankizumab for Induction and Maintenance of Remission in Crohn's DiseaseReena Khanna
Lancet (London, England)|February 25, 2016
Immunosuppression for management of Crohn's disease - Author's replyReena Khanna,
Gastroenterology|September 15, 2023
Upadacitinib for the Treatment of Crohn's DiseaseReena Khanna
Gastroenterology|April 7, 2017
Ustekinumab for Crohn's DiseaseReena Khanna, Waqqas Afif
Gastroenterology|February 6, 2021
Ustekinumab for Ulcerative ColitisReena Khanna, Waqqas Afif
Gastroenterology|October 4, 2016
Treatment Targets in Ulcerative ColitisReena Khanna, Vipul Jairath
Gastroenterology & Hepatology|August 31, 2012
Adverse metabolic sequelae following restorative proctocolectomy with an ileal pouchReena Khanna, Bo Shen
Gastroenterology|September 5, 2017
Is a Biosimilar Interchangeable With an Originator?Reena Khanna, Guangyong Zou
Inflammatory Bowel Diseases|November 21, 2023
The Use of Placebo in Clinical Trials of Inflammatory Bowel DiseasePavel S Roshanov, Reena Khanna
Pageof 17

Showing results (1-10 of 162) with videos related to

Sort By:
Pageof 17
Gastroenterology|February 2, 2025
The Safety and Efficacy of Guselkumab for the Treatment of Moderate to Severely Active Ulcerative ColitisReena Khanna
Gastroenterology|August 12, 2022
Risankizumab for Induction and Maintenance of Remission in Crohn's DiseaseReena Khanna
Lancet (London, England)|February 25, 2016
Immunosuppression for management of Crohn's disease - Author's replyReena Khanna,
Gastroenterology|September 15, 2023
Upadacitinib for the Treatment of Crohn's DiseaseReena Khanna
Gastroenterology|April 7, 2017
Ustekinumab for Crohn's DiseaseReena Khanna, Waqqas Afif
Gastroenterology|February 6, 2021
Ustekinumab for Ulcerative ColitisReena Khanna, Waqqas Afif
Gastroenterology|October 4, 2016
Treatment Targets in Ulcerative ColitisReena Khanna, Vipul Jairath
Gastroenterology & Hepatology|August 31, 2012
Adverse metabolic sequelae following restorative proctocolectomy with an ileal pouchReena Khanna, Bo Shen
Gastroenterology|September 5, 2017
Is a Biosimilar Interchangeable With an Originator?Reena Khanna, Guangyong Zou
Inflammatory Bowel Diseases|November 21, 2023
The Use of Placebo in Clinical Trials of Inflammatory Bowel DiseasePavel S Roshanov, Reena Khanna
Pageof 17